Table 4

Carotid IMT >0.90 mm and/or carotid plaques in a series of 201 rheumatoid arthritis patients categorised as having moderate risk (≥1% and <5%) after applying the modified SCORE*

Multiplication criteria†nCarotid IMT >0.90 mm and/or carotid plaques n (%)Carotid IMT >0.60 mm and/or carotid plaques n (%)
04023/40 (58)30/40 (75)
110161/101 (60)88/101 (87)
2 or 36042/60 (70)52/60 (86)
  • Patients were stratified according to the absence or presence of one or more of the three criteria proposed following the EULAR evidence-based recommendations for CV risk management in patients with rheumatoid arthritis.

  • *29 of the 230 patients categorised as having moderate CV risk according to the modified SCORE had type 2 diabetes or severe chronic kidney disease and, due to this, were excluded from this analysis. The percentage of patients with carotid IMT >0.90 mm and/or carotid plaques in the group of patients with moderate risk according to the modified SCORE did not depend on the number of multiplication criteria (p value=0.57; Fisher exact test).

  • †Disease duration of more than 10 years; RF and/or anti-CCP positivity; presence of certain extra-articular manifestations.

  • Anti-CCP, anticyclic citrullinated peptide; CV, cardiovascular; EULAR, European League Against Rheumatism; IMT, intima-media thickness; RF, rheumatoid factor; SCORE, systematic coronary risk evaluation.